{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:44:37Z","timestamp":1784810677883,"version":"3.55.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Clinical management of the rare and complex overlapping syndrome of MOG-antibody disease and anti-NMDAR encephalitis (MNOS), which has an uncertain pathogenesis and a high risk of recurrence, is highly challenging. We describe the case of a 19 years-old female patient, who first complained of headache, fever, and irritability. After that, she experienced frequent seizures and mood disorders. The diagnosis of MNOS was verified through antibody tests and imaging. For the patient, intravenous immunoglobulin and high-dose methylprednisolone were effective as first-line immunotherapy. Long-term immunotherapy with oral prednisone and mycophenolate mofetil was used to prevent relapses. However, over six years, the patient had five relapses when the mycophenolate mofetil dosage was reduced. The patient\u2019s condition stabilized after taking rituximab as second-line immunotherapy, with less than 1% of total lymphocytes being CD19+ cells. Eleven months later, the plasmablast ratio increased, and patients experienced new symptoms such as bilateral optic neuritis. After that, the patient got telitacicept injections regularly for 13 months, during which time her symptoms subsided, and there were no adverse effects or relapses. This case suggests that telitacicept may be a viable adjunct or sequential therapy option for the depletion of B cells in MNOS.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1509143","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:10:18Z","timestamp":1738825818000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Successful sequential therapy with rituximab and telitacicept in refractory Anti-NMDA receptor encephalitis and MOG-associated demyelination: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingliang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhe","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shougang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"577753","DOI":"10.1016\/j.jneuroim.2021.577753","article-title":"The changing spectrum of antibody-mediated encephalitis in China","volume":"361","author":"Ren","year":"2021","journal-title":"J Neuroimmunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2018.03.019","article-title":"An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis","volume":"320","author":"Zhou","year":"2018","journal-title":"J Neuroimmunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.09.023","article-title":"Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies","volume":"18","author":"Zhou","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.12.017","article-title":"A rare concurrence: Antibodies against Myelin Oligodendrocyte Glycoprotein and N-methyl-d-aspartate receptor in a child","volume":"28","author":"Sarigecili","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.01.007","article-title":"Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis","volume":"20","author":"Fan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01271","article-title":"Co-occurrence of anti-N-methyl-D-aspartate receptor encephalitis and anti-myelin oligodendrocyte glycoprotein inflammatory demyelinating diseases: A clinical phenomenon to be taken seriously","volume":"10","author":"Ren","year":"2019","journal-title":"Front Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti\u2013N-methyl-D-aspartate receptor encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.857443","article-title":"Clinical characteristics of anti-N-methyl-d-aspartate receptor encephalitis overlapping with demyelinating diseases: A review","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12036-y","article-title":"Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13904","article-title":"Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single-center, single-arm, open-label study","volume":"28","author":"Ding","year":"2022","journal-title":"CNS Neurosci Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit458","article-title":"Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium","volume":"57","author":"Venkatesan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1270011","article-title":"Case Report: Telitacicept in severe myasthenia gravis: a case study with multiple autoantibodies","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1279808","article-title":"Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies","volume":"14","author":"Ren","year":"2023","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"rkad088","DOI":"10.1093\/rap\/rkad088","article-title":"Good efficacy achieved by telitacicept, corticosteroids and immunosuppressants in the treatment of SLE combined with MOG-AD","volume":"7","author":"Tian","year":"2023","journal-title":"Rheumatol Adv Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16322","article-title":"A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis","volume":"31","author":"Yin","year":"2024","journal-title":"Eur J Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1400459","article-title":"Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"17562864241251476","DOI":"10.1177\/17562864241251476","article-title":"Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study","volume":"17","author":"Lin","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e39687","article-title":"Neuromyelitis optica spectrum disorder with ultra-longitudinally extensive transverse myelitis: A case report and literature review","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"B22","doi-asserted-by":"publisher","first-page":"keae601","DOI":"10.1093\/rheumatology\/keae601","article-title":"Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study","author":"Gao","year":"2024","journal-title":"Rheumatol Oxf Engl"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1456822","article-title":"Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1392992","article-title":"Efficacy of steroid therapy in the acute stage of anti-NMDAR and anti-MOG antibody overlapping encephalitis: a case report and literature review","volume":"15","author":"Kondo","year":"2024","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3390\/brainsci12080995","article-title":"Coexistence of myelin oligodendrocyte glycoprotein immunoglobulin G and neuronal or glial antibodies in the central nervous system: A systematic review","volume":"12","author":"Zhao","year":"2022","journal-title":"Brain Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.31083\/j.jin2103082","article-title":"Relapsing MOG-IgG-associated diseases coexisting with anti-NMDAR encephalitis: a case report and literature review","volume":"21","author":"Wang","year":"2022","journal-title":"J Integr Neurosci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","article-title":"Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis","volume":"10","author":"Dalmau","year":"2011","journal-title":"Lancet Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.711376","article-title":"Clinical features of coexisting anti-NMDAR and MOG antibody-associated encephalitis: A systematic review and meta-analysis","volume":"12","author":"Ding","year":"2021","journal-title":"Front Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009320","article-title":"Mystery Case: Anti-NMDAR encephalitis with overlapping demyelinating syndrome","volume":"94","author":"Kim","year":"2020","journal-title":"Neurology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.799454","article-title":"Case report: overlapping syndrome of anti-NMDAR encephalitis and MOG inflammatory demyelinating disease in a patient with human herpesviruses 7 infection","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1149987","article-title":"FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures overlaying anti-N-methyl-D-aspartate receptor encephalitis: a case report and literature review","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12883-022-02974-x","article-title":"Anti-NMDA receptor encephalitis and MOG-associated demyelination \u2013 a case report with long-term follow-up and a systematic review","volume":"22","author":"Berek","year":"2022","journal-title":"BMC Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"104442","DOI":"10.1016\/j.msard.2022.104442","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) in Chile: lessons learned from challenging cases","volume":"69","author":"Guzm\u00e1n","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"B34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000444161.12981.ba","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"82","author":"Kim","year":"2014","journal-title":"Neurology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02138","article-title":"Factors affecting early antibody secreting cell maturation into long-lived plasma cells","volume":"10","author":"Nguyen","year":"2019","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20111675","article-title":"B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6\u2013producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J Exp Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.203","article-title":"B cells and antibodies in multiple sclerosis pathogenesis and therapy","volume":"8","author":"Krumbholz","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci Transl Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1121705","article-title":"Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody","volume":"14","author":"Bai","year":"2023","journal-title":"Front Immunol"},{"key":"B43","unstructured":"Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences - PMC"},{"key":"B44","doi-asserted-by":"publisher","first-page":"104343","DOI":"10.1016\/j.ebiom.2022.104343","article-title":"Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity","volume":"86","author":"Robinson","year":"2022","journal-title":"eBioMedicine"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9709-9","article-title":"Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse","volume":"32","author":"Wang","year":"2012","journal-title":"J Clin Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jneuroim.2017.01.012","article-title":"Raised cerebrospinal fluid BAFF and APRIL levels in anti-N-methyl-d-aspartate receptor encephalitis: Correlation with clinical outcome","volume":"305","author":"Deng","year":"2017","journal-title":"J Neuroimmunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/bcp.12908","article-title":"Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS\/APRIL fusion protein, in patients with rheumatoid arthritis","volume":"82","author":"Chen","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: danger ahead","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211191","article-title":"Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus","volume":"76","author":"Md Yusof","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-017-1231-2","article-title":"Circulating plasmablasts\/plasma cells: a potential biomarker for IgG4-related disease","volume":"19","author":"Lin","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nri2637","article-title":"Dysregulation of germinal centres in autoimmune disease","volume":"9","author":"Vinuesa","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.325","article-title":"Evaluation and management of autoimmune pancreatitis: experience at a large US center","volume":"104","author":"Raina","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.596791","article-title":"Telitacicept following plasma exchange in the treatment of subjects with recurrent NMOSD: study protocol for a single-center, single-arm, open-label study","volume":"12","author":"Ding","year":"2021","journal-title":"Front Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1509143\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:10:22Z","timestamp":1738825822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1509143\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2025.1509143"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1509143","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"article-number":"1509143"}}